LTR PharmaASX:LTP +6.48%15 Receivables Turnover is 0.29 as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 841 Biotechnology companies, LTR Pharma ranks worse than 96.2% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. LTR Pharma's Revenue for the
six
months ended in Dec. 2025 was A$0.07 Mil. LTR Pharma's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$0.26 Mil.
Hence, LTR Pharma's Receivables Turnover for the
six
months ended in Dec. 2025 was 0.29.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
LTR Pharma Receivables Turnover Related Terms
LTR Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for LTR Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:LTP vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, LTR Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LTR Pharma Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LTR Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where LTR Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTR Pharma (ASX:LTP) has a Receivables Turnover of 0.29 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on LTR Pharma and its competitors. According to the industry distribution chart, LTR Pharma ranks #809 out of 841 companies in the Biotechnology industry, placing it in the top 96.2%.
Is LTR Pharma's Receivables Turnover too high?
LTR Pharma's current Receivables Turnover is 0.29. The Biotechnology industry median Receivables Turnover is 5.27. LTR Pharma's value of 0.29 is 94.5% below this industry median. Based on the distribution chart, LTR Pharma ranks #809 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #809 out of 841 companies for Receivables Turnover. This places LTR Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.27. LTR Pharma's value of 0.29 is 94.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LTR Pharma's current Receivables Turnover of 0.29 is 94.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on LTR Pharma and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LTR Pharma's current Receivables Turnover is 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current Receivables Turnover of 0.29. The current Receivables Turnover is 0.29 and 94.5% below the Biotechnology industry median of 5.27. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current Receivables Turnover is 0.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score
Get the complete analysis for ASX:LTP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LTP has been successfully added to your 